Literature DB >> 12151523

Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream.

Marco A Passini1, Edward B Lee, Gregory G Heuer, John H Wolfe.   

Abstract

A portion of the lysosomal enzymes produced by cells is secreted, diffuses through extracellular spaces, and can be taken up by distal cells via mannose-6-phosphate receptor-mediated endocytosis. This provides the basis for treating lysosomal storage diseases, many of which affect the CNS. Normal enzyme secreted from a cluster of genetically corrected cells has been shown to reverse storage lesions in a zone of surrounding brain tissue in mouse disease models. However, low levels of enzyme activity and reduction of storage lesions also have been observed at sites in the brain that may not be explained by a contiguous gradient of secreted enzyme diffusing away from the genetically corrected cells. No direct evidence for alternative mechanisms of enzyme transport has been shown, and little is understood about the intracellular movement of lysosomal enzymes in neurons. We investigated whether axonal transport could occur, by expressing an eukaryotic lysosomal enzyme that can be visualized in tissue sections (beta-glucuronidase) in brain structures that have defined axonal connections to other structures. This resulted in the transfer of enzyme to, and a reversal of storage lesions in, neurons that project to the gene expression site, but not in nearby structures that would have been corrected if the effect had been mediated by diffusion. In addition, transduction of cells in the subventricular zone resulted in the uptake of beta-glucuronidase by cells entering the rostral migratory stream. Gene transfer to specific neuronal circuits or cells in migratory pathways may facilitate delivery to the global brain lesions found in these disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151523      PMCID: PMC6758166          DOI: 20026665

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

Review 2.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 3.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

4.  Transgene expression in target-defined neuron populations mediated by retrograde infection with adeno-associated viral vectors.

Authors:  Markus Rothermel; Daniela Brunert; Christine Zabawa; Marta Díaz-Quesada; Matt Wachowiak
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

Review 5.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

Review 6.  Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.

Authors:  Adeline A Lau; Kim M Hemsley
Journal:  J Mol Med (Berl)       Date:  2017-06-29       Impact factor: 4.599

7.  Effective gene therapy in an authentic model of Tay-Sachs-related diseases.

Authors:  M Begoña Cachón-González; Susan Z Wang; Andrew Lynch; Robin Ziegler; Seng H Cheng; Timothy M Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

Review 8.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

9.  Delivery of proteins to CNS as seen and measured by positron emission tomography.

Authors:  Mikhail I Papisov; V Belov; A J Fischman; E Belova; J Titus; M Gagne; C Gillooly
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

10.  AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival.

Authors:  Rena C Baek; Marike L D Broekman; Stanley G Leroy; Laryssa A Tierney; Michael A Sandberg; Alessandra d'Azzo; Thomas N Seyfried; Miguel Sena-Esteves
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.